Harbin Medisan Pharmaceutical Co., Ltd. (SHE:002900)
China
· Delayed Price · Currency is CNY 11.95
-0.23 (-1.89%)
Mar 11, 2026, 11:34 AM CST
SHE:002900 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Net Income | -190.75 | 58.68 | 73.66 | 30.21 | 350.95 | 29.32 | Upgrade
|
| Depreciation & Amortization | 111.07 | 111.07 | 108.68 | 106.57 | 99.13 | 79.95 | Upgrade
|
| Other Amortization | 5.6 | 5.6 | 5.35 | 3.78 | 4.02 | 11.21 | Upgrade
|
| Loss (Gain) From Sale of Assets | -0.19 | -0.19 | 2.61 | 13.31 | 1.92 | 4.37 | Upgrade
|
| Asset Writedown & Restructuring Costs | 1.31 | 1.31 | -0.82 | 2.91 | -0.69 | -0.1 | Upgrade
|
| Loss (Gain) From Sale of Investments | -17.78 | -17.78 | -56.11 | -59.83 | -593.2 | 20.15 | Upgrade
|
| Provision & Write-off of Bad Debts | 1.22 | 1.22 | -2.86 | 0.59 | 1.8 | 4.06 | Upgrade
|
| Other Operating Activities | 349.53 | 27.34 | 1.51 | -2.38 | 16.1 | 6.63 | Upgrade
|
| Change in Accounts Receivable | -135.48 | -135.48 | -6.74 | -10.03 | 49.61 | 49.09 | Upgrade
|
| Change in Inventory | -98.88 | -98.88 | -46.8 | 0.62 | 26.49 | 31.87 | Upgrade
|
| Change in Accounts Payable | 76.7 | 76.7 | -51.42 | 47.19 | -63.69 | -239.62 | Upgrade
|
| Operating Cash Flow | 103.45 | 30.69 | 35.69 | 144.64 | -12.53 | -4.51 | Upgrade
|
| Operating Cash Flow Growth | - | -14.02% | -75.32% | - | - | - | Upgrade
|
| Capital Expenditures | -235.14 | -346.21 | -299.58 | -89.22 | -73.95 | -145.85 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.19 | 0.03 | 0.22 | 0.27 | 11.61 | 0.58 | Upgrade
|
| Cash Acquisitions | - | - | -15.98 | - | - | - | Upgrade
|
| Divestitures | - | - | - | - | -4.05 | - | Upgrade
|
| Investment in Securities | -35 | -6.08 | 46.69 | 500 | -227.73 | 318.74 | Upgrade
|
| Other Investing Activities | 44.16 | 20.85 | 8.12 | 8.21 | 15.89 | 27.82 | Upgrade
|
| Investing Cash Flow | -225.79 | -331.41 | -260.52 | 419.25 | -278.23 | 201.29 | Upgrade
|
| Long-Term Debt Issued | - | 859.55 | 280 | 431 | 471.6 | 319.51 | Upgrade
|
| Total Debt Issued | 948.19 | 859.55 | 280 | 431 | 471.6 | 319.51 | Upgrade
|
| Long-Term Debt Repaid | - | -643.77 | -242.47 | -274.74 | -282.46 | -230 | Upgrade
|
| Total Debt Repaid | -813 | -643.77 | -242.47 | -274.74 | -282.46 | -230 | Upgrade
|
| Net Debt Issued (Repaid) | 135.19 | 215.77 | 37.53 | 156.26 | 189.14 | 89.51 | Upgrade
|
| Repurchase of Common Stock | -0.22 | -0.22 | -1.17 | - | - | - | Upgrade
|
| Common Dividends Paid | -109.57 | -104.56 | -41.04 | -109.34 | -34.31 | -95.79 | Upgrade
|
| Other Financing Activities | 215 | 202.85 | -10.41 | -154.04 | -198.53 | 3.73 | Upgrade
|
| Financing Cash Flow | 240.4 | 313.85 | -15.08 | -107.12 | -43.71 | -2.56 | Upgrade
|
| Net Cash Flow | 118.07 | 13.12 | -239.91 | 456.77 | -334.48 | 194.23 | Upgrade
|
| Free Cash Flow | -131.69 | -315.52 | -263.89 | 55.42 | -86.48 | -150.36 | Upgrade
|
| Free Cash Flow Margin | -15.06% | -27.86% | -22.23% | 5.39% | -9.14% | -11.23% | Upgrade
|
| Free Cash Flow Per Share | -0.42 | -1.02 | -0.86 | 0.18 | -0.28 | -0.46 | Upgrade
|
| Cash Income Tax Paid | 41.13 | 42.26 | 92.12 | 85.85 | 74.74 | 130.31 | Upgrade
|
| Levered Free Cash Flow | -68.42 | -366.52 | -243.03 | 83.23 | -28.2 | -219.31 | Upgrade
|
| Unlevered Free Cash Flow | -51.05 | -347.16 | -228.72 | 97.37 | -19.57 | -213.48 | Upgrade
|
| Change in Working Capital | -156.54 | -156.54 | -96.32 | 49.49 | 107.42 | -160.1 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.